Oxford Gene Technology (OGT) Company Profile

12:46 EDT 19th March 2019 | BioPortfolio

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. The company has two trading businesses, Biomarker Discovery and Clinical & Genomic Solutions. Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies. Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

News Articles [2039 Associated News Articles listed on BioPortfolio]

Oxford Gene Technology: Mike Evans. Providers of innovative genetics research and biomarker solutions to advance molecular medicine

Mike Evans, CEO of Oxford Gene Technology talks to Fintan Walton about OGT's new diagnostic techiques and innovative research into Lupus, Prostate and Colorectal cancers.

Amgen invests £50m in UK genetics firm Oxford Nanopore

Biotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its cutting-edge technology. US firm Amgen has invested in Oxford Nanopore, which has dev...

Gene therapy breakthrough in treating rare form of blindness

The world’s first gene therapy trial for a genetic cause of blindness known as choroideremia has shown positive results. The trial, supported by NIHR Oxford Biomedical Research Centre (BRC), began i...

Oxford Firm Launches to Develop Quantum-Era Sensor Technology

Oxford HighQ, a spinout from Oxford University, aims to revolutionise chemical and nanoparticle sensor technology with ‘quantum’ sensors up to 10,000 times more sensitive than current coun...

Microsoft Research and Oxford Biomedica Collaborate to Improve Gene Therapy Using Intelligent Cloud and Machine Learning

Oxford, UK – 12 March 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, today announces that it has entered into a research and development collaboration with Microso...

Thermo and Oxford Genetics expand CRISPR toolkits with ERS deals

Thermo Fisher and Oxford Genetics have announced separate plans to partner with ERS Genomics, gaining access to CRISPR gene editing technology.

Amgen Invests $66 Million in Oxford Nanopore Technologies

THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen’s equity investment of £5...

CRISPR gene editing technology license extended

Oxford Genetics has extended its CRISPR gene editing technology license agreement from ERS Genomics to support its international growth

PubMed Articles [3128 Associated PubMed Articles listed on BioPortfolio]

Inferring gene expression networks with hubs using a degree weighted Lasso approach.

Genome-scale gene networks contain regulatory genes called hubs that have many interaction partners. These genes usually play an essential role in gene regulation and cellular processes. Despite recen...

A new era of gene editing for the treatment of human diseases.

The treatment of human diseases using gene-editing technology has been envisioned for several decades with the realisation that so many were associated with mutations in DNA. The Human Genome Project ...

Diagnosis and characterization of canine distemper virus through sequencing by MinION nanopore technology.

Prompt identification of the causative pathogen of an infectious disease is essential for the choice of treatment or preventive measures. In this perspective, nucleic acids purified from the brain tis...

Phylogenetic approaches to identifying fragments of the same gene, with application to the wheat genome.

As the time and cost of sequencing decrease, the number of available genomes and transcriptomes rapidly increases. Yet the quality of the assemblies and the gene annotations varies considerably and of...

A Bayesian model for single cell transcript expression analysis on MERFISH data.

Multiplexed error-robust fluorescence in-situ hybridization (MERFISH) is a recent technology to obtain spatially resolved gene or transcript expression profiles in single cells for hundreds to thousan...

Clinical Trials [3685 Associated Clinical Trials listed on BioPortfolio]

Oxford Partial Knee Replacement. A Randomized Clinical Trial of Three Implant Types

The purpose of this scientific study is to clarify whether there is a relationship between the appearance of radiolucent lines in bone-cement interphase of the tibial component of the diff...

Comparison of Oxford UKA and Sigma UKA With RSA.

Comparison of two unicompartmental knee arthroplasties (UKA), to see if Sigma UKA performs equally good as the Oxford UKA. The study focuses on how well the arthroplasty is fixated to the ...

A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System

The purpose of this study is to collect information on complications and survivorship of patients implanted with the Oxford™ Meniscal Unicompartmental Knee System at multiple sites in th...

Oxford® Partial Knee Kinematics Gait Analysis Study

The objective of this study is to compare the effect on gait of unicompartmental knee arthroplasty (UKA), using the Oxford® Partial Knee, versus total knee arthroplasty (TKA), using the V...

Outcome Analysis of the Oxford Partial Knee Arthroplasty

Prospectively monitor the patients receiving the Oxford Partial knee arthroplasty

Companies [1093 Associated Companies listed on BioPortfolio]

Oxford BioMedica plc

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the...

Oxford Healthcare Technology

Oxford Healthcare Technology is a staffing firm that leverages their recruiting expertise to deliver experienced healthcare professionals and project teams for consulting engageme...

Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

BioMedica Inc.

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was esta...

Oxford Gene Technology

DNA microassays consisting of in situ synthesises oligonucleotide probes.

More Information about "Oxford Gene Technology (OGT)" on BioPortfolio

We have published hundreds of Oxford Gene Technology (OGT) news stories on BioPortfolio along with dozens of Oxford Gene Technology (OGT) Clinical Trials and PubMed Articles about Oxford Gene Technology (OGT) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oxford Gene Technology (OGT) Companies in our database. You can also find out about relevant Oxford Gene Technology (OGT) Drugs and Medications on this site too.

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record